NasdaqGS:BEAMBiotechs
Assessing Beam Therapeutics (BEAM) Valuation After ARK Invest Expands Its Position
ARK Invest recently expanded its position in Beam Therapeutics (BEAM), adding more than 195,000 shares as it leans further into precision genetic medicines and base-editing approaches to address serious inherited diseases.
See our latest analysis for Beam Therapeutics.
The ARK purchase comes as Beam Therapeutics trades at US$28.34, with a 1 day share price return of 5.59% and a year to date share price return of 4.42%. The 1 year total shareholder return of 4.65% sits against a 5 year total...